PsyFi

We sat down with Stephen Barnhill, MD of Aion Therapeutic, Inc.

Dr. Barnhill is a physician, fellowship trained in Laboratory Medicine and Board Certified by the American Board of BioAnalysis, an expert in artificial intelligence, an inventor on more than 40 patents globally and is an experienced pharmaceutical and biotech executive with experience as a CEO in both private and public companies in the United States and internationally. Previously, he was Founder, Chairman and CEO of a U.S. publicly-traded international biotech company, which he took from inception to profitability. Throughout his career, Dr. Barnhill has negotiated and executed deals with many companies including Pfizer, Corning-MetPath, Quest Diagnostics, Clarient (now GE Healthcare), LabCorp, NeoGenomics, Abbott, Bruker and others. He has published many papers with academics including those from MD Anderson Cancer Center, Johns Hopkins University Medical Center, Stanford University Medical Center and others.

Dr. Barnhill is a pioneer in artificial intelligence and machine learning (pattern recognition algorithms) and is an inventor on more than 40 patents globally including neural networks and support vector machines including the Hallmark SVM-RFE technique now cited by more than 10,000 publications. His patents were part of the intellectual property portfolio that won 1st Place out of 1600 publicly traded companies and was awarded the MICO award from MDB Capital for the most disruptive intellectual property portfolio. Dr. Barnhill’s Neural network patents were acquired by Johnson and Johnson. He was an inventor on patents related to laboratory developed tests and tumor markers, as well as, diagnostic test development relating to cancers of the prostate, pancreas, breast and ovary, cytogenetics, flow cytometry, FISH and imaging in digital mammography, funduscopic analysis of macular degeneration (AMD) and he was part of the team that launched the first SVM iPhone app using artificial intelligence for melanoma detection.

Dr. Barnhill is currently Executive Chairman of Aion Therapeutic Inc. and Chairman and CEO of AI Pharmaceuticals Jamaica limited, a wholly-owned subsidiary of Aion Therapeutic Inc. He is also Chairman and CEO of Doc’s Place International, Inc., the first Global Center of Excellence for Medical Cannabis Therapy in Jamaica, Chairman and CEO of Apollon Formularies, Inc. (United States), President and Board Member Apollon Formularies Jamaica, Ltd. (Jamaica) and Chairman and CEO of Apollon Formularies, Ltd. (United Kingdom).

We sit down with Dr. Joseph Tucker, CEO of MagicMed Industries.

During his two decades of biotechnology C-Suite leadership Dr. Tucker cofounded four companies, taking two public and selling one, while the fourth remains an operating private company. He has raised tens of millions of dollars from investors in the United States, Europe and Canada, during which time his teams took seven drugs into FDA, EMA, and HC-approved clinical trials. Among other achievements Dr. Tucker, in collaboration with Dr. Peter Facchini, was the first to sequence the entire genome of the commercially relevant Papaver somniferum, is a co-inventor of cardiovascular drug candidate APABETALONE, and is the discoverer of the human blindness-associated gene SLC24A1. Dr. Tucker has published in high-ranking journals such as Nature Biotechnology and Nature Chemical Biology, has been interviewed by national newspapers and television, is an inventor on 7 issued and 15 pending patents, and holds a Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.